DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer. 2023

Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
Department of Colorectal Cancer, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, No. 651, Dongfeng Road East, Guangzhou, 510060, Guangdong, People's Republic of China.

BACKGROUND For clinically low-risk stage III colorectal cancer, the decision on cycles of adjuvant chemotherapy after surgery is disputed. The present study investigates the use of additional biomarkers of ploidy and stroma-ratio(PS) to stratify patients with low-risk stage III colorectal cancer, providing a basis for individualized treatment in the future. METHODS This study retrospectively enrolled 198 patients with clinical-low-risk stage III colorectal cancer (T1-3N1M0) and analyzed the DNA ploidy and stroma ratio of FFPE tumor tissues. The patients were divided into PS-low-risk group (Diploidy or Low-stroma) and PS-high-risk group (Non-diploid and High-stroma). For survival analyses, Kaplan-Meier and Cox regression models were used. RESULTS The results showed that the 5-year DFS of the PS-high-risk group was significantly lower than that in the PS-low-risk group (78.6 vs. 91.2%, HR = 2.606 [95% CI: 1.011-6.717], P = 0.039). Besides, in the PS-low-risk group, the 5 year OS (98.2 vs. 86.7%, P = 0.022; HR = 5.762 [95% CI: 1.281-25.920]) and DFS (95.6, vs 79.9%, P = 0.019; HR = 3.7 [95% CI: 1.24-11.04]) of patients received adjuvant chemotherapy for > 3 months were significantly higher than those received adjuvant chemotherapy for < 3 months. We also found that the PS could stratify the prognosis of patients with dMMR tumors. The 5-year OS (96.3 vs 71.4%, P = 0.037) and DFS (92.6 vs 57.1%, P = 0.015) were higher in the PS-low-risk dMMR patients than those in the PS-high-risk dMMR patients. CONCLUSIONS In this study, we found that PS can predict the prognosis of patients with stage III low-risk CRC. Besides, it may guide the decision on postoperative adjuvant chemotherapy.

UI MeSH Term Description Entries
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011003 Ploidies The degree of replication of the chromosome set in the karyotype. Ploidy
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
September 2020, British journal of cancer,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
July 2022, The journal of pathology. Clinical research,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
October 2019, Anticancer research,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
January 1996, World journal of surgery,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
March 2018, Annals of oncology : official journal of the European Society for Medical Oncology,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
April 2023, The Journal of pathology,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
December 2016, Journal of gastrointestinal cancer,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
January 2013, ISRN gastroenterology,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
September 2022, Medical science monitor : international medical journal of experimental and clinical research,
Yuan Li, and Leen Liao, and Lingheng Kong, and Wu Jiang, and Jinghua Tang, and Kai Han, and Zhenlin Hou, and Chenzhi Zhang, and Chi Zhou, and Linjie Zhang, and Qiaoqi Sui, and Binyi Xiao, and Weijian Mei, and Yanbo Xu, and Jiehai Yu, and Zhigang Hong, and Zhizhong Pan, and Peirong Ding
April 2023, Cancer medicine,
Copied contents to your clipboard!